Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan

BACKGROUND: Asia has a high burden of hepatocellular carcinoma (HCC) due to the high rates of chronic hepatitis B infection and accounts for 70% of HCC cases globally. In the past 20 years, the systemic treatment landscape of advanced HCC has evolved substantially − from tyrosine kinase inhibitors t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yau, Thomas, Tai, David, Chan, Stephen Lam, Huang, Yi-Hsiang, Choo, Su Pin, Hsu, Chiun, Cheung, Tan To, Lin, Shi-Ming, Yong, Wei Peng, Lee, Joycelyn, Leung, Thomas, Shum, Tracy, Yeung, Cynthia S.Y., Tai, Anna Yin-Ping, Law, Ada Lai Yau, Cheng, Ann-Lii, Chen, Li-Tzong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485972/
https://www.ncbi.nlm.nih.gov/pubmed/36158587
http://dx.doi.org/10.1159/000525582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485972/
https://www.ncbi.nlm.nih.gov/pubmed/36158587
http://dx.doi.org/10.1159/000525582

Ejemplares similares